Upon administration of AlCl3 in the AD group, the serum levels of tau protein and phosphorylated tau were 2-fold and 3.6-fold higher than the control group, respectively, while the serum level of neurogranin (NG) declined to half of the control, confirming the success of the AD model (Table 2). This evidence concerns the gene MAPT and Alzheimer disease.